Table 2. Detected pretreatment serum levels of identified biomarkers.
| Biomarkers | Pretreatment serum levels | P Value | Foldchange | |
|---|---|---|---|---|
| ENI (n = 19) | Non ENI (n = 19) | |||
| Mean ± standard deviation, pg/ml | ||||
| CCL-23 | 505.32±416.14 | 224.57±141.14 | 0.006 | 1.99 |
| CXCL-12 | 1244.39±5178.59 | 20.33±20.97 | 0.004 | 5.00 |
| IGFBP-6 | 53450.38±8664.92 | 42904.08±8448.38 | 0.002 | 1.25 |
| IL-5 | 212.50±203.96 | 96.42±92.19 | 0.009 | 2.46 |
| LYVE-1 | 1389.22±144.92 | 1089.21±242.02 | <0.001 | 1.30 |
| PAI-1 | 17523.08±4691.52 | 11918.16±4343.32 | <0.001 | 1.52 |
| PDGF-AA | 2434.21±479.85 | 1810.86±649.86 | <0.001 | 1.41 |
| ST-2 | 146.39±198.39 | 48.56±62.75 | 0.009 | 3.73 |
| TNF-α | 153.72±221.95 | 58.29±89.10 | 0.006 | 5.77 |
ENI, early neurologic improvement; CCL-23, chemokine (C-C motif) ligand 23; CXCL-12, chemokine (C-X-C motif) ligand 12; IGFBP-6, insulin-like growth factor binding protein 6; IL-5, interleukin 5; LYVE-1, lymphatic vessel endothelial hyaluronan receptor 1; PAI-1, plasminogen activator inhibitor 1; PDGF-AA, platelet-derived growth factor AA; ST-2, suppression of tumorigenicity 2; TNF-α, tumor necrosis factor α.